Compare CABA & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | AIV |
|---|---|---|
| Founded | 2017 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.7M | 435.9M |
| IPO Year | 2019 | 1996 |
| Metric | CABA | AIV |
|---|---|---|
| Price | $2.63 | $2.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $14.50 | $10.00 |
| AVG Volume (30 Days) | ★ 6.7M | 1.6M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 87.41% |
| EPS Growth | 10.26 | ★ 616.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $138,486,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $2.73 |
| 52 Week High | $4.23 | $8.82 |
| Indicator | CABA | AIV |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 25.16 |
| Support Level | $2.11 | N/A |
| Resistance Level | $3.40 | $3.01 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 4.72 | 21.43 |
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.